People - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

People
People on the move

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 4

People

People on the move

New York, NY (Apr. 17)Bristol-Myers Squibb Company . ( http://www.bms.com/)announced that James M. Cornelius, who has served as interim chief executive for the past eight months, has been elected chief executive officer with a term through the date of the company's annual meeting of stockholders in 2009.

Cornelius has been a member of the Bristol-Myers Squibb board since January of 2005, previously serving as chairman and CEO of Guidant Corporation, chief financial officer of Eli Lilly and Company, and president and CEO of IVAC Corporation..

Cambridge, MA (Apr. 18)Molecular Insight Pharmaceuticals, Inc. ( http://www.molecularinsight.com/) named Brian Abeysekera, PhD, vice-president of manufacturing. Abeysekera joins the company after more than 20 years at MDS Nordion.

Ann Arbor, MI (Apr. 18)–Kay E. Stremler was appointed vice-president of manufacturing at Pipex Pharmaceuticals, Inc. ( http://www.pipexpharma.com/). Stremler was previously director, bioprocess research and development and clinical supply, pharmaceutical sciences for Esperion Therapeutics. She also was responsible for GMP manufacturing at Boehringer-Ingelheim Pharma KG.

Bridgewater, NJ (Apr. 17)–Jeffrey S. Campbell was promoted to executive vice-president and chief financial officer of Alpharma, Inc. ( http://www.alpharma.com/). Campbell joined the company as vice-president and controller in October 2002 and has been acting as interim chief financial officer since September 2006.

Raleigh, NC (Apr. 17)–J. Scott Mohrland, PhD, was named president and chief executive officer of Erimos Pharmaceuticals ( http://www.erimos.com/). Before joining Erimos, Mohrland served as executive vice-president of GMP Companies, Inc.

Basel, Switzerland (Apr. 12)Novartis ( http://www.novartis.com/) appointed Joseph Jimenez chief executive officer of its consumer-health division. Jimenez replaces Paul Choffat, who is retiring at the end of April. Jimenez joins the company from private-equity firm The Blackstone Group.

Thousand Oaks, CA (Apr. 10)Amgen ( http://www.amgen.com/) promoted Robert Bradway to executive vice-president and chief financial officer. Bradway joined Amgen in 2006, after 18 years with Morgan Stanley.

Tarrytown, NY (Apr. 10)Emisphere Technologies, Inc. ( http://www.emisphere.com/) named Michael V. Novinski president and chief executive officer. Novinski joins the company from Organon USA Inc., where he served as president. He replaces Lewis Bender, who was appointed interim chief executive officer January 16, 2007.

Memphis, TN (Apr. 10)–Jeff Hesselberg was appointed vice-president of regulatory affairs with GTx, Inc. ( http://www.gtxinc.com/). Hesselberg joins GTx from ICOS, where he served as director of regulatory affairs.

Durham, NC (Apr. 10)–M. Nixon Ellis, PhD, was appointed president and chief executive officer of Phase Bioscience, Inc. ( http://www.phasebio.com/). Ellis was president of Trimeris, Inc. and cofounder, president, chief operating officer. and director of Triangle Pharmaceuticals, Inc.

Marlborough, MA (Apr. 9)Xcellerex, Inc. ( http://www.xcellerex.com/) appointed John Chickosky chief operating officer. Chickosky joins the company after holding management positions at Kendro Laboratory Products, CARR Separations, and Sepracor.

Buffalo Grove, IL (Apr. 5)–Shawn L. Silvestri, PhD, was appointed vice-president, new product development at Akorn, Inc. ( http://www.akorn.com/). Silvestri previously served as director, Abbott Diagnostics Division Focused Factory and Technical Services with Abbott Laboratories.

Montvale, NJ (Apr. 4)Intranasal Therapeutics, Inc. ( http://www.intranasal.com/) named Peter F. Young president and chief executive officer. Young was most recently president and CEO of AlphaVax.

Coral Gables, FL (Apr. 4)–Catalyst Pharmaceuticals Partners, Inc. ( http://www.catalystpharma.com/) appointed Steven R. Miller, PhD, vice-president of pharmaceutical development and project management. Miller will be responsible for the company's product development program, including all aspects of chemistry and manufacturing controls, quality systems, contract operations, and development planning. Miller previously was executive director of R&D operationsn with Watson Laboratories.

Parsippany, NJ (Apr. 3)–Joseph Marchese joined DSM Pharmaceuticals Inc. ( http://www.dsm.com/) as senior director, business manager, sterile injectables. Marchese served as vice-president of sales and marketing at West-Ward Pharmaceutical Corp.

Paris (Apr. 3)-Ipsen ( http://www.ipsen.com/) named Eric Drape executive vice-president, manufacturing and supply organization. Drape succeeds Peter Wilson, who is retiring from the company.

San Francisco, CA (Apr. 3)–Philip J. Young was appointed president and chief executive officer of Osteologix Inc. ( http://www.osteologix.com/). Young joins the company from Insmed, Inc., where he was chief business officer and executive vice-president.

San Diego, CA (Apr. 3)Somaxon Pharmaceuticals, Inc. ( http://www.somaxon.com/) appointed James L'Italien, PhD, senior vice-president, regulatory affairs and quality assurance. L'Italien assumes the newly created position after serving as senior vice-president, regulatory affairs and compliance at Ligand Pharmaceuticals. He also held positions at Baxter BioScience, Amylin, Ortho Biotech, and SmithKline Beecham.

London (Apr. 3)Amarin Corporation plc ( http://www.amarincorp.com/) appointed Paul F. Duffy president of US commercial operations. Duffy previously held positions with Novartis Pharmaceuticals and Validus Pharmaceuticals.

Portage, IN (Apr. 2)MonoSol Rx ( http://www.monosolrx.com/) appointed Larry W. Kranking senior vice-president of pharmaceutical operations. Kranking previously was president of thecontract manufacturing company Lang Medikaments, Inc. While employed with Esai Inc., Kranking managed the design, construction, qualification, and FDA approval of the company's parenteral and solid-dose drug development and commercial operations facility.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here